809
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Diagnostics for tuberculosis: what test developers want to know

Pages 311-314 | Published online: 09 Jan 2014

References

  • Weyer K, Mirzayev F, Migliori GB et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF. Eur. Resp. J. doi:10.1183/09031936.00157212 (2012) (Epub ahead of print).
  • Steingart KR, Sohn H, Schiller I et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst. Rev. 1, CD009593 (2013).
  • Pai M. Tuberculosis diagnostics: test developers’ FAQs. Int. J. Tuberc. Lung Dis. 17(5), 570–571 (2013).
  • Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev. Mol. Diagn. 12(7), 687–701 (2012).
  • Pai NP, Pai M. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov. Med. 13(68), 35–45 (2012).
  • Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 45–55 (2012).
  • Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 9(9), e1001306 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.